TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

[1]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[2]  T. Kaisho,et al.  Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.

[3]  夏秋 洋平.  Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin , 2016 .

[4]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[5]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[6]  M. Headley,et al.  Visualization of immediate immune responses to pioneer metastatic cells in the lung , 2016, Nature.

[7]  Simon C Watkins,et al.  Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation , 2015, The Journal of experimental medicine.

[8]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[9]  E. Winer,et al.  Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[11]  F. Rosenbauer,et al.  Batf3 maintains Irf8 autoactivation for commitment of a CD8α+ cDC clonogenic progenitor , 2015, Nature Immunology.

[12]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[13]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[14]  S. Coffelt,et al.  Immune-mediated mechanisms influencing the efficacy of anticancer therapies. , 2015, Trends in immunology.

[15]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[17]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[18]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[19]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[20]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[21]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[22]  A. Iwasaki,et al.  A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells , 2014, Science.

[23]  Mamta Gupta,et al.  Immunoregulation of Dendritic Cells by the Receptor T cell Ig and Mucin Protein-3 via Bruton’s Tyrosine Kinase and c-Src , 2014, The Journal of Immunology.

[24]  J. Harty,et al.  Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection , 2014, The Journal of Immunology.

[25]  G. Plitas,et al.  Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy , 2013, The Journal of experimental medicine.

[26]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[27]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[28]  H. Yoshiyama,et al.  Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas , 2013, Cancer Immunology, Immunotherapy.

[29]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[30]  J. Egen,et al.  Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. , 2013, Immunity.

[31]  A. Rieger,et al.  TIM-3 Does Not Act as a Receptor for Galectin-9 , 2013, PLoS pathogens.

[32]  S. Nutt,et al.  CD8α+ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. , 2013, Blood.

[33]  Sheng Xiao,et al.  Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion , 2012, Nature Medicine.

[34]  H. Yoshiyama,et al.  Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[36]  Mikala Egeblad,et al.  Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.

[37]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[38]  H. Makino,et al.  Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. , 2012, Endocrinology.

[39]  L. Kane,et al.  Galectin-9 regulates T helper cell function independently of Tim-3. , 2011, Glycobiology.

[40]  J. Penninger,et al.  Brief Definitive Report , 2003 .

[41]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[42]  V. Kuchroo,et al.  Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways , 2011, Molecular and Cellular Biology.

[43]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[44]  Pedro Romero,et al.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.

[45]  Gordon K Smyth,et al.  Id2 expression delineates differential checkpoints in the genetic program of CD8α+ and CD103+ dendritic cell lineages , 2011, The EMBO journal.

[46]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[47]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[48]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[49]  Yuan Qi,et al.  Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer , 2010, Clinical Cancer Research.

[50]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[51]  L. Kane.  T Cell Ig and Mucin Domain Proteins and Immunity , 2010, The Journal of Immunology.

[52]  K. Takeda,et al.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. , 2009, Blood.

[53]  R. Kaul,et al.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection , 2008, The Journal of experimental medicine.

[54]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[55]  David E. Anderson,et al.  Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells , 2007, Science.

[56]  A. Yamauchi,et al.  Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a mirine model of allergic asthma , 2007, American journal of respiratory and critical care medicine.

[57]  J. Bonventre,et al.  A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. , 2006, Biochemical and biophysical research communications.

[58]  H. Tajiri,et al.  Preferential Involvement of Tim-3 in the Regulation of Hepatic CD8+ T Cells in Murine Acute Graft-versus-Host Disease1 , 2006, The Journal of Immunology.

[59]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Michael G. Johnson,et al.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.

[61]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[62]  J. Sprent,et al.  T cell memory. , 2003, Annual review of immunology.

[63]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[64]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[66]  María Martínez-López,et al.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. , 2016, Cancer discovery.

[67]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[68]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[69]  M. Smyth,et al.  Microenvironment and Immunology Anti-TIM 3 Antibody Promotes T Cell IFN-g – Mediated Antitumor Immunity and Suppresses Established Tumors , 2011 .